Literature DB >> 17333051

[Diagnostics for pulmonary tuberculosis in adults].

G Laifer1, S Bassetti.   

Abstract

The incidence of pulmonary tuberculosis (TB) is decreasing in Western Europe. However, TB should not be considered to be a rare disease, particularly in immigrants and in immunocompromised persons (i.e. HIV infection). The clinical presentation is often atypical in immunocompromised persons. In general, the extent of the disease is underestimated by the clinical presentation. X-ray and a sequential investigation of three samples of sputum including microscopy, culture and susceptibility testing for the first-line drugs should be obtained. Tuberculin testing is useful in the diagnosis of latent TB and in screening persons with close contact to patients with active disease. New blood tests based on the detection of interferon-g released by antigen specific T-cells have some advantages compared to tuberculin testing.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17333051     DOI: 10.1007/s00108-007-1814-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  18 in total

1.  Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection.

Authors:  J Y Lee; H J Choi; I-N Park; S-B Hong; Y-M Oh; C-M Lim; S D Lee; Y Koh; W S Kim; D S Kim; W D Kim; T S Shim
Journal:  Eur Respir J       Date:  2006-04-12       Impact factor: 16.671

2.  Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis?

Authors:  Madhukar Pai; Dick Menzies
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

3.  Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2006-03-24       Impact factor: 17.586

4.  Influence of bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size?

Authors:  F Tissot; G Zanetti; P Francioli; J-P Zellweger; F Zysset
Journal:  Clin Infect Dis       Date:  2004-12-20       Impact factor: 9.079

5.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis.

Authors:  A Telenti; P Imboden; F Marchesi; D Lowrie; S Cole; M J Colston; L Matter; K Schopfer; T Bodmer
Journal:  Lancet       Date:  1993-03-13       Impact factor: 79.321

6.  Incidence and significance of acid-fast bacilli in sputum smears at the end of antituberculous treatment.

Authors:  R Vidal; N Martin-Casabona; A Juan; T Falgueras; M Miravitlles
Journal:  Chest       Date:  1996-06       Impact factor: 9.410

7.  Microscopic-observation drug-susceptibility assay for the diagnosis of TB.

Authors:  David A J Moore; Carlton A W Evans; Robert H Gilman; Luz Caviedes; Jorge Coronel; Aldo Vivar; Eduardo Sanchez; Yvette Piñedo; Juan Carlos Saravia; Cayo Salazar; Richard Oberhelman; Maria-Graciela Hollm-Delgado; Doris LaChira; A Roderick Escombe; Jon S Friedland
Journal:  N Engl J Med       Date:  2006-10-12       Impact factor: 91.245

8.  Smallpox vaccination and adverse reactions. Guidance for clinicians.

Authors:  Joanne Cono; Christine G Casey; David M Bell
Journal:  MMWR Recomm Rep       Date:  2003-02-21

9.  Polymerase chain reaction for Mycobacterium tuberculosis: impact on clinical management of refugees with pulmonary infiltrates.

Authors:  Gerd Laifer; Andreas F Widmer; Reno Frei; Werner Zimmerli; Ursula Fluckiger
Journal:  Chest       Date:  2004-03       Impact factor: 9.410

Review 10.  Tuberculosis.

Authors:  Thomas R Frieden; Timothy R Sterling; Sonal S Munsiff; Catherine J Watt; Christopher Dye
Journal:  Lancet       Date:  2003-09-13       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.